<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611232</url>
  </required_header>
  <id_info>
    <org_study_id>LiraAAB18-30</org_study_id>
    <secondary_id>2014-003667-37</secondary_id>
    <secondary_id>3-SRA-2014-301-M-R</secondary_id>
    <secondary_id>U1111-1176-6062</secondary_id>
    <nct_id>NCT02611232</nct_id>
  </id_info>
  <brief_title>Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults</brief_title>
  <official_title>Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of the trial are to study whether daily treatment with liraglutide
      improves insulin secretion and glucose metabolism, and whether liraglutide treatment is
      tolerable and safe in subjects with preclinical type 1 diabetes aged 18-30 years.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FPIR (first phase insulin response)</measure>
    <time_frame>From baseline to 26 and 104 weeks</time_frame>
    <description>First phase insulin response during 10-min IVGTT (intravenous glucose tolerance test )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia</measure>
    <time_frame>From baseline to 26 and 104 weeks</time_frame>
    <description>Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>From baseline to 26 and 104 weeks</time_frame>
    <description>Tolerability: frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-peptide AUC</measure>
    <time_frame>From baseline to 26 and 104 weeks</time_frame>
    <description>Serum C-peptide area under the curve (AUC) during 2-hour OGTT (oral glucose tolerance test)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Victoza®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Victoza®</intervention_name>
    <description>Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.</description>
    <arm_group_label>Victoza®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-30 years of age

          -  positive for at least 2 biochemical islet autoantibodies

          -  have normal glucose tolerance in OGTT

          -  are not pregnant

        Exclusion Criteria:

          -  allergic to liraglutide or other ingredients of Victoza®

          -  Type 1 diabetes

          -  diabetic ketoacidosis

          -  previous treatment in the last three months with any antidiabetic medication

          -  impaired liver or kidney function or on dialysis

          -  severe heart failure

          -  severe stomach or gut problem resulting in gastroparesis, or inflammatory bowel
             disease

          -  past or current history of pancreatitis

          -  serum calcitonin value above normal (&gt;50 ng/l or ≥3.4pmol/l)

          -  presence of any chronic metabolic, hematologic or malignant disease

          -  obesity BMI ≥30

          -  pregnant females and females of childbearing potential who are not using adequate
             contraceptive methods.

          -  breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riitta Veijola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oulu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oulu and Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tampere and Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turku and Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Riitta Veijola</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes Type 1</keyword>
  <keyword>Diabetes, Insulin-Dependent</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Preclinical Type 1 Diabetes</keyword>
  <keyword>GLP-1 Analogue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

